Trial Profile

A Prospective, Randomized Phase III Study to Compare the Effects of Paclitaxel and Topotecan to Those of Cisplatin and Topotecan for Treatment of Patients With Recurrent and Persistent Cervical Cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Topotecan (Primary) ; Cisplatin; Paclitaxel
Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms AGO-Zervix-1

28 Mar 2022 This trial has been completed in Belgium (End Date: 02 Apr 2014), according to European Clinical Trials Database record.
19 Feb 2022 This trial has been completed in Germany (End Date: 02 Apr 2014), according to European Clinical Trials Database record.
06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003652).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com